Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy

Eun Jin Go; Hannah Yang; Hong Jae Chon; Dasom Yang; Wonhyoung Ryu; Dong Hyun Kim; Dong Keun Han; Chan Kim; Wooram Park

doi:10.3390/cancers12113123

Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy

Eun Jin Go, Hannah Yang, Hong Jae Chon, Dasom Yang, Wonhyoung Ryu, Dong Hyun Kim, Dong Keun Han^*, Chan Kim^*, Wooram Park^*

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.

Original language	English (US)
Article number	3123
Pages (from-to)	1-15
Number of pages	15
Journal	Cancers
Volume	12
Issue number	11
DOIs	https://doi.org/10.3390/cancers12113123
State	Published - Nov 2020

Keywords

Cancer immunotherapy
Combinational treatment
Immunogenic cell death (ICD)
Irreversible electroporation (IRE)
Stimulator of IFN genes (STING) agonists

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers12113123

Cite this

@article{801570f6e93247a6b9616189e851fd8f,

title = "Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy",

abstract = "Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.",

keywords = "Cancer immunotherapy, Combinational treatment, Immunogenic cell death (ICD), Irreversible electroporation (IRE), Stimulator of IFN genes (STING) agonists",

author = "Go, {Eun Jin} and Hannah Yang and Chon, {Hong Jae} and Dasom Yang and Wonhyoung Ryu and Kim, {Dong Hyun} and Han, {Dong Keun} and Chan Kim and Wooram Park",

note = "Funding Information: Funding: This work was supported by the National Research Foundation (NRF) of Korea. The grant was funded by the Ministry of Science and ICT (MSIT), Republic of Korea (2018R1C1B6001120, 2020M2D9A3094208, 2020R1A2C2004530, and 2020R1A2B5B03002344). Funding Information: This work was supported by the National Research Foundation (NRF) of Korea. The grant was funded by the Ministry of Science and ICT (MSIT), Republic of Korea (2018R1C1B6001120, 2020M2D9A3094208, 2020R1A2C2004530, and 2020R1A2B5B03002344). Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = nov,

doi = "10.3390/cancers12113123",

language = "English (US)",

volume = "12",

pages = "1--15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy

AU - Go, Eun Jin

AU - Yang, Hannah

AU - Chon, Hong Jae

AU - Yang, Dasom

AU - Ryu, Wonhyoung

AU - Kim, Dong Hyun

AU - Han, Dong Keun

AU - Kim, Chan

AU - Park, Wooram

N1 - Funding Information: Funding: This work was supported by the National Research Foundation (NRF) of Korea. The grant was funded by the Ministry of Science and ICT (MSIT), Republic of Korea (2018R1C1B6001120, 2020M2D9A3094208, 2020R1A2C2004530, and 2020R1A2B5B03002344). Funding Information: This work was supported by the National Research Foundation (NRF) of Korea. The grant was funded by the Ministry of Science and ICT (MSIT), Republic of Korea (2018R1C1B6001120, 2020M2D9A3094208, 2020R1A2C2004530, and 2020R1A2B5B03002344). Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/11

Y1 - 2020/11

N2 - Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.

AB - Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.

KW - Cancer immunotherapy

KW - Combinational treatment

KW - Immunogenic cell death (ICD)

KW - Irreversible electroporation (IRE)

KW - Stimulator of IFN genes (STING) agonists

UR - http://www.scopus.com/inward/record.url?scp=85095729178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095729178&partnerID=8YFLogxK

U2 - 10.3390/cancers12113123

DO - 10.3390/cancers12113123

M3 - Article

C2 - 33114476

AN - SCOPUS:85095729178

SN - 2072-6694

VL - 12

SP - 1

EP - 15

JO - Cancers

JF - Cancers

IS - 11

M1 - 3123

ER -

Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this